Previous 10 | Next 10 |
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for treatment of soft tissue sarcomas - - Enrolling across SPEARHEAD-1 and SURPASS trials at multiple sites ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third Quarter 2019 and provide a business update, before the U.S. markets open on Wed...
In our most recent article, we focused on Iovance ( IOVA ), a cell therapy company that in our opinion has consistently generated positive data, has developed a commercializable product, and is deploying a de-risked clinical strategy for a clear unmet need. As a result, we saw nearly 100% ups...
Adaptimmune Therapeutics ( ADAP ) is a good speculative biotech to look into in considering to add to the portfolio. That's because it announced some preliminary positive data in patients with synovial sarcoma . On the flip side, the data was only achieved in a phase 1 study. There is a c...
Adaptimmune Therapeutics (NASDAQ: ADAP ) announces a 3-year agreement with Cryoport (NASDAQ: CYRX ) to use latter's logistics solutions for its cell therapies. More news on: Adaptimmune Therapeutics plc, Cryoport, Inc., Healthcare stocks news, Read more ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperatur...
Gainers: Akcea Therapeutics (NASDAQ: AKCA ) +29% . Liquid Media Group (NASDAQ: YVR ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +20% . Sutro Biopharma (NASDAQ: STRO ) +19% . Livongo Health (NASDAQ: LVGO ) +15% . Motus GI Holdings (NASDAQ: MOTS ) +12% . Teekay Tankers (NYSE: TNK )...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as interim Chief Financial Officer (CFO) effective immediately. ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from patients with synovial sarcoma who were treated in the ongoing Phase 1 trial with SP...
Gainers: Francesca's Holdings (NASDAQ: FRAN ) +92% . Mallinckrodt plc (NYSE: MNK ) +64% . Pier 1 Imports (NYSE: PIR ) +41% . YRC Worldwide (NASDAQ: YRCW ) +32% . Endo International (NASDAQ: ENDP ) +29% . Dean Foods Company (NYSE: DF ) +28% . Basic Energy Services (NYSE: BAS ) ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...